2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. SHP2

SHP2

Src homology phosphatase 2; PTPN11

Src-homology-2-containing protein tyrosine phosphatase 2 (SHP2), encoded by the PTPN11 gene, is a 593 amino acid classical non-receptor protein tyrosine phosphatase (PTP). SHP2 is involved in diverse signalling pathways such as RAS-MAPK, PI3K-AKT, JAK-STAT and PD-1/PD-L1. Besides, SHP2 negatively regulates the activation of recombinant NLRP3 (NLR family, pyrin domain containing protein 3) inflammasome via mitochondrial homeostasis. SHP2 has been regarded as an extremely attractive target for human diseases therapies, particular in cancer.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-125260
    SHP844
    		Inhibitor
    SHP844 is a SHP2 inhibitor with the IC50 of 18.9 µM. SHP2 is a protein tyrosine phosphatase (PTP) that regulates tyrosine phosphorylation levels and is involved in cell proliferation, differentiation and survival.
    SHP844
  • HY-171960
    SHP2-IN-40
    		Inhibitor
    SHP2-IN-40 (Compound 25) is an inhibitor of SHP2 with an AC50 of 0.0107 μM. SHP2-IN-40 can be used in the research of cancer.
    SHP2-IN-40
  • HY-N10079
    Suchilactone
    		Inhibitor
    Suchilactone (Jatrophan) is a lignan extracted from Monsonia angustifolia E.Mey. Suchilactone binds to SHP2 and inhibits SHP2 activation, thereby inhibiting ERK-mediated cell proliferation. Suchilactone can be ued in acute myeloid leukaemia (AML).
    Suchilactone
  • HY-155277
    SHP2-IN-21
    SHP2-IN-21 (compound 208) is a SHP2 inhibitor with an IC50 value of 3 nM. SHP2-IN-21 can be used for glioblastoma research.
    SHP2-IN-21
  • HY-181800
    SHP2-IN-47
    		Inhibitor
    SHP2-IN-47 is a selective and potent SHP2 inhibitor with an IC50 of 0.80 μM. SHP2-IN-47 exhibits potent inhibitory activity against SHP2E76K (IC50 = 0.37 μM). SHP2-IN-47 functionally inhibits protein tyrosine phosphatase domains and downregulates SHP2-mediated phosphorylation of AKT and ERK. SHP2-IN-47 induces apoptosis and suppresses proliferation of cancer cells. SHP2-IN-47 can be used for the research of cancer, such as acute myelocytic leukemia.
    SHP2-IN-47
  • HY-155274
    SHP2-IN-18
    SHP2-IN-18 (compound 183) is a SHP2 inhibitor with an IC50 value of 3 nM. SHP2-IN-18 can be used for glioblastoma research.
    SHP2-IN-18
  • HY-176796
    SHP2-IN-43
    		Inhibitor
    SHP2-IN-43 (Compound 5) is a SHP2 inhibitor with an IC50 of 98.7 nM. SHP2-IN-43 can be used as a PROTAC target ligand in the synthesis of SHP2-D26 (HY-145162).
    SHP2-IN-43
  • HY-162755
    SHP2-IN-30
    		Inhibitor
    SHP2-IN-30 (compound 14i) is an allosteric SHP2 inhibitor with an IC50 of 104 nM. SHP2-IN-30 shows low inhibitory effect on SHP2-PTP. SHP2-IN-30 induces cell apoptosis and arrests the cell cycle at the G0/G1 phase.
    SHP2-IN-30
  • HY-158762
    TK-642
    		Inhibitor
    TK-642 is a highly active, selective, orally activity SHP2 inhibitor based on pyrazole and pyrazine (IC50=2.7 nmol/L). TK-642 can effectively inhibit the proliferation of esophageal carcinoma cells and induce cell apoptosis. TK-642 can be used in the study of esophageal cancer.
    TK-642
  • HY-P3444A
    CD31 TFA
    CD31 (PECAM-1) TFA is platelet endothelial cell adhesion molecule-1, serves as the endothelial cell-specific receptor of clostridium perfringens b-Toxin (CPB). CD31 TFA is also an ER-MP12 antigen, acts as a linker between mechanical stress, metabolism and inflammation. CD31 TFA peptide is able to sustain phosphorylation of the CD31 ITIM686 and of SHP2 and to inhibit TCR-induced T-cell activation-.
    CD31 TFA
  • HY-159489
    SDUY038
    		Inhibitor
    SDUY038 is a SHP2 allosteric inhibitor, with an IC50 of 1.2 μM and KD of 0.29 μM, respectively. SDUY038 exhibits pan-antitumor activity (IC50 = 7-24 μM) by suppressing pERK expression. SDUY038 exhibits t1/2 of 3.95 h by oral administration.
    SDUY038
  • HY-173571
    TK-685
    		Inhibitor
    TK-685 is an orally active, selective, and allosteric SHP2 inhibitor with an IC50 of 2.1 nM. TK-685 inhibits esophageal cancer cell proliferation and induced apoptosis by targeting SHP2-mediated AKT and ERK signaling pathways.
    TK-685
  • HY-141524
    RMC-3943
    		Inhibitor
    RMC-3943 is an allosteric SHP2 inhibitor (inhibition of full-length SHP2 in biochemical assay, IC50 = 2.19 nM).
    RMC-3943
  • HY-125259
    SHP504
    		Inhibitor
    SHP504 is a SHP2 phosphatase inhibitor, with an IC50 of 21 μM for SHP21–525.
    SHP504
  • HY-157535
    SHP2-IN-24
    		Inhibitor
    SHP2-IN-24 (compound 111675) is a potent SHP2 inhibitor with an IC50 value of 0.878 µM and a Ki value of 0.118 µM.
    SHP2-IN-24
  • HY-169918
    SHP2-IN-34
    		Inhibitor
    SHP2-IN-34 (compound A8) is a phenyl urea SHP2 inhibitor with anti-cancer activity. SHP2-IN-34 significantly suppresses tumor growth in CT26 mouse model.
    SHP2-IN-34
  • HY-100388R
    SHP099 (Standard)
    		Inhibitor
    SHP099 (Standard) is the analytical standard of SHP099. This product is intended for research and analytical applications. SHP099 is an allosteric SHP2 inhibitor, with IC50s of 0.690, 1.241, 0.416, 1.968, 2.896 μM for SHP2, SHP2D61Y, SHP2E69K, SHP2A72V, SHP2E76K. SHP099 inhibits cancer cell growth, such as MV4-11 and TF-1 cell (IC50: 0.32 and 1.73 μM). SHP099 inhibits RAS-ERK signaling and inhibits tumor growth.
    SHP099 (Standard)
  • HY-100388AR
    SHP099 monohydrochloride (Standard)
    		Inhibitor
    SHP099 (monohydrochloride) (Standard) is the analytical standard of SHP099 (monohydrochloride). This product is intended for research and analytical applications. SHP099 hydrochloride is a potent, selective and orally available SHP2 inhibitor with an IC50 of 70 nM.
    SHP099 monohydrochloride (Standard)
  • HY-N12915
    SHP2-IN-29
    		Inhibitor
    SHP2-IN-29 (Compound 3) is a potent SHP2 inhibitor with an IC50 value of 0.18 μM. SHP2-IN-29 also has inhibitory activity against PTP1B and TCPTP, with IC50 values of 4.27 and 4.74 μM, respectively.
    SHP2-IN-29
  • HY-174322
    SHP2-IN-38
    		Inhibitor
    SHP2-IN-38 is a novel green-fluorescent SHP2 inhibitor with IC50 values of 2.89 μM (SHP2), 8.73 μM (SHP1), 11.08 μM (PTP1B), 33.07 μM (TCPTP). SHP2-IN-38 blocks the SHP2-mediated ERK signaling pathway and inhibits MV4-11 cells proliferation in vitro with IC50 of 7.90 μM. SHP2-IN-38 has an excitation wavelength of 360 nm, with a maximum emission wavelength of 550 nm in DMSO and 540 nm in DMF. SHP2-IN-38 shows green fluorescence imaging in HeLa cells and zebrafish.
    SHP2-IN-38
Cat. No. Product Name / Synonyms Application Reactivity